Andere Sprachen Petros Pharmaceuticals

Aktien

A3D2B6

US71678J2096

PTPI

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
0,6399 ^USD	0,00 %		-4,51 %	-54,62 %

23.04.	Petros und Lemonaid Health arbeiten zusammen, um die Verfügbarkeit von Stendra auszuweiten	MT
23.04.	Petros Pharmaceuticals, Inc. erweitert den Online-Vertrieb für verschreibungspflichtiges STENDRA durch neue Vereinbarung mit Lemonaid Health	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health	25.04.
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA through New Agreement with Lemonaid Health	24.04.
Petros, Lemonaid Health Collaborate to Expand Stendra Availability	23.04.
Petros Pharmaceuticals, Inc. Expands Online Distribution for Prescription STENDRA Through New Agreement with Lemonaid Health	23.04.
Petros Gets 'Positive' FDA Response Over Technology Component in Stendra OTC Process	16.04.
Petros Pharmaceuticals Receives Positive Response from Fda Following Recent Demonstration of Technology Component in Pursuit of Otc Status for Stendra(R)	16.04.
Petros Pharmaceuticals, Inc. Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA as it Pursues OTC Status	02.04.
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc	11.03.
Petros Pharmaceuticals Enters into Ai Licensing Agreement with Leading Multi-Billion-Dollar Software Provider	14.02.
Thinking about buying stock in Helius Medical Technologies, Peraso, GDS Holdings, Everbridge, or Petros Pharmaceuticals?	06.02.
Top Premarket Gainers	30.01.
Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA Rx-to-OTC Switch	25.01.
Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA Rx-to-OTC Switch	18.01.
Petros Pharmaceuticals, Inc. Announces Successful Completion of the Initial Cohort of A Phase 2 Equivalent Self-Selection Study	17.01.
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA the First Erectile Dysfunction Medication to Achieve OTC Status	13.12.
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's OTC Switch Technology Provider	13.12.
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) the First Erectile Dysfunction Medication to Achieve OTC Status	12.12.
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug Crestor's (Rosuvastatin) OTC Switch Technology Provider	05.12.
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Petros Pharmaceuticals

Aktien

A3D2B6

US71678J2096

PTPI

Andere Sprachen

Filter